Our recent study showed that the presence of CLSs expressing the inhibitory FcγRIIB (CD32B) at the tumour border was associated with worse clinical outcomes in patients with HER2+ breast cancer treated with trastuzumab compared to trastuzumab-naïve patients [45]. The gene discussed is ERBB2; the disease is neoplasm.